Tien Liang BioTech Co (ROCO:4127) PE Ratio: 595.33 (As of Aug. 07, 2026) — 2232% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4127 Tien Liang BioTech Co Ltd ROCO:4127
36 GF Score
Price NT$89.30
GF Value NT$45.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tien Liang BioTech Co PE Ratio?

Tien Liang BioTech Co ROCO:4127 +3.84% 36 PE Ratio is 595.33 as of Aug. 07, 2026, which is 2232% above its 10-year median of 25.53. GuruFocus rates ROCO:4127 with a GF Score™ of 36/100 and a GF Value™ of NT$45.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-07), Tien Liang BioTech Co's share price is NT$89.30. Tien Liang BioTech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.15. Therefore, Tien Liang BioTech Co's PE Ratio for today is 595.33.

Warning Sign:

Tien Liang BioTech Co Ltd stock PE Ratio (=566) is close to 10-year high of 566.

During the past 13 years, Tien Liang BioTech Co's highest PE Ratio was 595.33. The lowest was 7.70. And the median was 25.53.

Tien Liang BioTech Co's EPS (Diluted) for the three months ended in Mar. 2026 was NT$0.75. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.15.

As of today (2026-08-07), Tien Liang BioTech Co's share price is NT$89.30. Tien Liang BioTech Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.15. Therefore, Tien Liang BioTech Co's PE Ratio without NRI ratio for today is 595.33.

During the past 13 years, Tien Liang BioTech Co's highest PE Ratio without NRI was 595.33. The lowest was 7.70. And the median was 25.53.

Tien Liang BioTech Co's EPS without NRI for the three months ended in Mar. 2026 was NT$0.75. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.15.

During the past 12 months, Tien Liang BioTech Co's average EPS without NRI Growth Rate was -68.80% per year.

During the past 13 years, Tien Liang BioTech Co's highest 3-Year average EPS without NRI Growth Rate was 36.70% per year. The lowest was -40.40% per year. And the median was 9.70% per year.

Tien Liang BioTech Co's EPS (Basic) for the three months ended in Mar. 2026 was NT$0.75. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.15.

Back to Basics: PE Ratio


Tien Liang BioTech Co  (ROCO:4127) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Tien Liang BioTech Co PE Ratio Related Terms


Tien Liang BioTech Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co PE Ratio Chart

Tien Liang BioTech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.51 11.88 37.18 159.62 At Loss

Tien Liang BioTech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.54 At Loss At Loss At Loss 240.00

ROCO:4127 vs ZTS: PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tien Liang BioTech Co PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tien Liang BioTech Co's PE Ratio falls into.


ROCO:4127
36GF Score
Tien Liang BioTech Co Ltd ROCO:4127
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tien Liang BioTech Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Tien Liang BioTech Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=89.30/0.150
=595.33

Tien Liang BioTech Co's Share Price of today is NT$89.30.
Tien Liang BioTech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.15.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 595.33 mean?
Tien Liang BioTech Co (ROCO:4127) has a PE Ratio of 595.33 as of Aug. 07, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Tien Liang BioTech Co and its competitors. This is 2232% above median its historical median of 25.53. Over the past decade, Tien Liang BioTech Co's PE Ratio has ranged from 7.70 to 595.33.
Is Tien Liang BioTech Co's PE Ratio too high?
Tien Liang BioTech Co's current PE Ratio of 595.33 is 2232% above median its 10-year median of 25.53. Over the past 10 years, this metric has ranged from a low of 7.70 to a high of 595.33. Overall, Tien Liang BioTech Co has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's PE Ratio compare to ZTS?
Tien Liang BioTech Co's PE Ratio of 595.33 can be compared against companies in the Drug Manufacturers industry. Historically, Tien Liang BioTech Co's own PE Ratio has ranged from 7.70 to 595.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Tien Liang BioTech Co and its competitors. Tien Liang BioTech Co's current PE Ratio is 595.33, which is 2232% above median its own 10-year median of 25.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$45.56, compared to a current price of NT$89.30 — trading 96% above its estimated fair value. The current PE Ratio is 595.33, which is 2232% above median its 10-year median of 25.53. Tien Liang BioTech Co's overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current PE Ratio is 595.33 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$89.30 is trading 96% above its estimated GF Value™ of NT$45.56. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

  • PE Ratio: 595.33 (2232% above median its 10-year median of 25.53)
  • GF Value™: NT$45.56 vs. price of NT$89.30 (96% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tien Liang BioTech Co Business Description

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
36GF Score

Get the complete analysis for ROCO:4127

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$89.30
Price
NT$45.56
GF Value